Jade Biosciences Announces Proposed Underwritten Public Offering
Rhea-AI Summary
Jade Biosciences (Nasdaq: JBIO) plans a proposed underwritten public offering of common stock and, for certain investors, pre-funded warrants to buy common shares. All securities will be sold by Jade, with underwriters receiving a 30-day option for up to 15% additional securities. Proceeds are intended to fund clinical trials, preclinical studies, manufacturing, R&D, capital spending, working capital and general corporate purposes.
Positive
- Proposed equity financing to support clinical, preclinical and manufacturing programs
- Existing shelf registration on Form S-3 effective May 15, 2026 facilitates offering access
Negative
- New shares and pre-funded warrants would increase share count if the offering is completed
News Market Reaction – JBIO
In the Jun 4 session, JBIO gained 0.85%, reflecting a mild positive market reaction. Argus tracked a peak move of +19.4% during that session. Argus tracked a trough of -7.5% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 01 | Phase 1 interim data | Positive | -11.6% | Positive interim Phase 1 JADE101 data with ~70% IgA reduction at 12 weeks. |
| May 29 | Data call announcement | Positive | -11.6% | Announcement of webcast to discuss interim Phase 1 JADE101 results. |
| May 26 | First-in-human start | Positive | -1.0% | First participant dosed in Phase 1 trial of JADE201 for autoimmune diseases. |
| May 26 | Phase 2 trial start | Positive | -2.3% | First participant dosed in JUNIPER Phase 2 trial of JADE101 in IgA nephropathy. |
| May 07 | Q1 2026 earnings | Positive | +6.6% | Q1 2026 results with $311.3M liquidity and detailed development milestones. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows multiple positive clinical and corporate updates followed by negative 24h price reactions, with only the Q1 2026 earnings update seeing a positive move.
Over the last month, Jade reported several key milestones, including positive interim Phase 1 results for JADE101 (Jun 1, 2026) and first dosing in Phase 1 and Phase 2 trials for JADE201 and JADE101 in late May 2026. Despite fundamentally constructive clinical progress, each of these trial-related announcements saw negative next-day moves. By contrast, the May 7, 2026 Q1 earnings and corporate update, highlighting $311.3 million in cash and investments, coincided with a positive price reaction. Today’s underwritten offering follows this sequence of capital- and development-focused news.
Key Terms
underwritten public offering financial
pre-funded warrants financial
book-running managers financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in a proposed underwritten public offering. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering are being offered by Jade. In addition, Jade intends to grant the underwriters a 30-day option to purchase up to an additional
Jade intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents, and investments, to fund clinical trials, preclinical studies, and manufacturing in support of its programs, as well as for additional research and development activities, capital expenditures, working capital and other general corporate purposes.
Jefferies, TD Cowen and UBS Investment Bank are acting as joint book-running managers for the proposed offering. LifeSci Capital is also acting as a book-running manager for the proposed offering. BTIG is acting as a lead manager for the proposed offering.
The securities described above are being offered by Jade pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (“SEC”) and was declared effective on May 15, 2026. A preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. Copies of the prospectus supplement for this offering may be obtained, when available, by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; and UBS Securities LLC, Attention: Prospectus Department, 11 Madison Avenue, New York, NY 10010, or by email at ol-prospectus-request@ubs.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Jade Biosciences, Inc.
Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an undisclosed antibody program. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
Forward Looking Statements
Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, our expectations regarding the completion, timing, structure and size of the proposed offering and our intended use of net proceeds therefrom, and the grant of the option to purchase additional shares. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as the other risks, uncertainties and factors more fully described in Jade’s most recent filings with the Securities and Exchange Commission (including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and its subsequent filings). Should one or more of these risks or uncertainties materialize, or should any of Jade’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements, except as required by law. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade.
Jade Biosciences Contact
Priyanka Shah
Media@JadeBiosciences.com
IR@JadeBiosciences.com
908-447-6134
